Daniel Kingsbury
Pediatric Rheumatology · Portland, ORNPI 1396705414
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,095 of the $4,113 with a category attached, or 99.6%. Pfizer accounts for 99.6% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2020 at $3,145 and has fallen 99.4% since, to $18 in 2025.
Across 5 payments — averaging $822.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4K
- GSK$18
Across 285 payments — averaging $5383.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$552K
- AbbVie$333K
- Janssen Research & Development, LLC$205K
- Pfizer$135K
- UCB GmbH$125K
- Novartis Pharma AG$87K
- plus $97K from 2 others
What the payments were for
- Speaking & faculty fees$4,095100%
- Food & beverage$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XELJANZ$950
How this compares
Too few pediatric rheumatology providers in Oregonto place this figure against a meaningful peer group, so we don't.
Other pediatric rheumatology in Portland
- Andrew LaskyPortland$118
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.